Neurobehavioral Mechanisms of Choice in Opioid Use Disorder
NCT03958474
Recruiting
The objective of this protocol is to use probabilistic reinforcement learning choice tasks and magnetic resonance neuroimaging to demonstrate the impact of problematic opioid use and opioid withdrawal on dynamic decision-making and reveal the neurobehavioral and neurobiological processes underlying abnormal task performance. A second objective is to identify an appropriate dose of intravenous remifentanil for subsequent studies in physically dependent individuals with opioid use disorder.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/17/2025
Locations: Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky
Conditions: Opioid Use Disorder
Register for Updates
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022
Recruiting
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), fol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona +56 locations
Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Iron Supplementation and Intestinal Health
NCT04497012
Recruiting
This is a randomized double-blinded study of enteral iron supplementation in Very Low Birth Weight infants. The subjects will be randomized into low dose (2 mg/kg/day) and high dose (6 mg/kg/day) of daily iron supplementation. The primary outcomes are intestinal health including microbiome, inflammation, and barrier function.
Gender:
ALL
Ages:
Between 1 day and 6 months
Trial Updated:
01/17/2025
Locations: Tampa General Hospital, Tampa, Florida
Conditions: Anemia of Prematurity, Very Low Birth Weight Infant
Register for Updates
Mechanisms for Activation of Beige Adipose Tissue in Humans
NCT04666636
Recruiting
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Gender:
ALL
Ages:
Between 35 years and 65 years
Trial Updated:
01/17/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: PreDiabetes
Register for Updates
Liver Transplantation for Unresectable Liver Limited Colorectal Metastases
NCT04742621
Recruiting
This is a single-arm, single institution pilot registry of liver transplantation in patients with unresectable colorectal liver-only metastases at Weill Cornell Medical College. Patients with liver predominant colorectal liver metastases will be screened based on eligibility criteria in a specified clinical hepatobiliary and colorectal liver metastasis tumor board consisting of the principal and co-investigators, representing medical oncology, transplant surgery, radiology, and pathology. The re... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/17/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Unresectable Liver-limited Colorectal Metastases
Register for Updates
Pulmonary Hypertension SOLAR
NCT04778046
Recruiting
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Register for Updates
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320
Recruiting
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
01/17/2025
Locations: Phoenix Childrens Hospital, Phoenix, Arizona +95 locations
Conditions: Crohn's Disease (CD)
Register for Updates
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
NCT04933435
Recruiting
This is a research study to evaluate change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30), from baseline to 1 month post treatment in two patient cohorts receiving Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Durham Veterans Administration Health Care System (DVAHCS), Durham, North Carolina +1 locations
Conditions: Liver Cancer
Register for Updates
Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI
NCT04941573
Recruiting
This study will use Magnetic Resonance Imaging (MRI) to study the lungs of 90 volunteers using the inhaled contrast agent, hyperpolarized xenon-129. Once inhaled, this gas can provide information to imagers regarding lung functionality across specific regions of the lungs by assessing the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the natural spongy tissue structure has been compromised by lung disease. Of the 90 subjects, 70 will be patient... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/17/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Transplant Rejection
Register for Updates
Reducing Fall Risk With NMES
NCT04969094
Recruiting
Falls are dangerous leading to injuries, hospital admissions and even death. Fall prevention is a priority but effective programs only reduce falls by 30%. Weak hip muscles may be one reasons individuals experience a loss of balance. However individuals who have weak hip muscles may be unable to exercise at sufficient intensities to improve their hip muscle strength. The purpose of this study is to utilize a common physical therapy method, neuromuscular electrical stimulation (NMES), on the hip... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
01/17/2025
Locations: Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland
Conditions: Falls
Register for Updates
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
NCT05051436
Recruiting
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Gender:
ALL
Ages:
Between 35 years and 65 years
Trial Updated:
01/17/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Pre-diabetes, Obesity
Register for Updates
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983
Recruiting
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Gender:
ALL
Ages:
Between 1 day and 6 months
Trial Updated:
01/17/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +10 locations
Conditions: Tuberous Sclerosis Complex, Epilepsy
Register for Updates